ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

β-メチル-L-チロシン

Metyrosine

HCID 441350
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
672-87-7
標準SMILES
C[C@](N)(Cc1ccc(O)cc1)C(=O)O
InChIKey
NHTGHBARYWONDQ-JTQLQIEISA-N
分子式
C10H13NO3
平均分子量
195.21 g/mol
単同位体質量
195.08954328

概要

Alpha-methyl-L-tyrosine is an L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. It has a role as an antihypertensive agent and an EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor. It is a L-tyrosine derivative and a non-proteinogenic L-alpha-amino acid.

名称と識別子

優先名称
Metyrosine
IUPAC
(2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid
現地名
β-メチル-L-チロシン
英語名
alpha-Methyl-L-p-tyrosine
分子式
C10H13NO3
分子量
195.22

名称と別名

METYROSINE672-87-7MetirosineDemserMetirosina(2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid(S)-alpha-MethyltyrosineL-alpha-MethyltyrosineMetirosinum(-)-alpha-Methyl-L-tyrosineAlpha-Methyl-L-P-TyrosineMK-781
名称をさらに表示
メチロシンデムセル(S)-2-アミノ-3-(4-ヒドロキシフェニル)-2-メチルプロパン酸(-)-α-メチル-L-チロシンα-メチル-L-チロシンα-メチルチロシン(S)-2-アミノ-2-メチル-3-(4-ヒドロキシフェニル)プロピオン酸(S)-2-アミノ-3-(4-ヒドロキシフェニル)-2-メチルプロピオン酸2-メチル-L-チロシン(S)-α-アミノ-β-(4-ヒドロキシフェニル)-α-メチルプロピオン酸(S)-3-(2-メチル-4-ヒドロキシフェニル)-2-アミノプロピオン酸β-メチル-L-チロシン(S)-Α-メチル-4-ヒドロキシフェニルアラニン(S)‐Α‐メチル‐4‐ヒドロキシフェニルアラニンメチロシン (JAN)(2S)-2-アミノ-3-(4-ヒドロキシフェニル)-2-メチルプロパン酸α-メチルパラタイロシンα-Methyl-L-tyrosineα-Me-Tyr-OHAMPTL-AMPTL-α-MTa-Me-Tyr-OHL-Metyrosine
DTXSID6023315DOQ0J0TPF7CHEBI:6912L-588357-0DTXCID203315methyl-tyrosineRefChem:56543alpha-Methyltyrosine, (L)-

物性

構造計算による物性

XLogP
-1.6
極性表面積
83.6 Ų
水素結合供与体数
3
水素結合受容体数
4
回転可能結合数
3
重原子数
14
形式電荷
0
複雑度
211

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
LogP-1.7
Solubility · 2 件

Very slightly soluble

2.48e+00 g/L

Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point312.5 °C
Physical DescriptionSolid

物理化学的性質

融点
320 · 320-340°C dec.
沸点
383.7 · 383.7±32.0 °C(Predicted)
比重(密度)
1.283 · 1.283±0.06 g/cm3(Predicted)
貯蔵温度
-20 °C · -20°C
溶解性
水性酸(わずかに)
外見
粉
酸解離定数(Pka)
2.7 · pKa 2.7 (Uncertain);10.1 (Uncertain)
色
白色~淡黄色
Merck
13 · 13,6183

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P270, P271, P301+P317, P304+P340, P319, P330, P403+P233, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 4 (100%)

毒性情報

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Metyrosine

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

安全データ

wgk
3
tsca
No
hs_code
2922504500
risk_code
22-38-40-48/20/22
safety_code
22-24/25
ストレージクラス
11 - Combustible Solids

化学と産業

薬理情報

ATC Code · 2 件

C - Cardiovascular system

QC - Cardiovascular system

Pharmacodynamics · 1 件

In patients with pheochromocytoma, who produce excessive amounts of norepinephrine and epinephrine, administration of one to four grams of metyrosine per day has reduced catecholamine biosynthesis from about 35 to 80 percent as measured by the total excretion of catecholamines and their metabolites (metanephrine and vanillylmandelic acid). The maximum biochemical effect usually occurs within two to three days, and the urinary concentration of catecholamines and their metabolites usually returns to pretreatment levels within three to four days after metyrosine is discontinued. Most patients with pheochromocytoma treated with metyrosine experience decreased frequency and severity of hypertensive attacks with their associated headache, nausea, sweating, and tachycardia. In patients who respond, blood pressure decreases progressively during the first two days of therapy with metyrosine; after withdrawal, blood pressure usually increases gradually to pretreatment values within two to three days.

Mechanism of Action · 1 件

Metyrosine inhibits tyrosine hydroxylase, which catalyzes the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA). Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines and their synthesis. This consequently, depletes the levels of the catecholamines dopamine, adrenaline and noradrenaline in the body,usually measured as decreased urinary excretion of catecholamines and their metabolites. One main end result of the catecholamine depletion is a decrease in blood presure.

Biological Half-Life3.4 to 3.7 hours
Metabolism/MetabolitesLittle biotransformation, with catechol metabolites accounting for less than 1% of the administered dose.
FDA Pharmacological Classification · 6 件

DOQ0J0TPF7

関連反応

5 件
反応記録を作成
HRID 78951 の反応式
HRID 78951生成物として
HRID 78954 の反応式
HRID 78954生成物として
HRID 1980390 の反応式
HRID 1980390生成物として
HRID 2230273 の反応式
HRID 2230273反応物として
HRID 2289418 の反応式
HRID 2289418反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
672-87-7
PubChem CID
441350
DTXSID
DTXSID6023315
ChEMBL
CHEMBL1200862
ChEBI
CHEBI:6912
UNII
DOQ0J0TPF7
EC Number
211-599-5
Nikkaji
J9.465J
BRN
2368400 · 2368400
InChI
InChI=1/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/s3
InChIKey
NHTGHBARYWONDQ-JTQLQIEISA-N
SMILES
C(C1C=CC(O)=CC=1)[C@@](N)(C)C(=O)O |&1:8,r|
CAS データベース
672 · 672-87-7(CAS DataBase Reference)

化学的性質

化学的特性White Solid

METYROSINE

Established Pharmacologic Class [EPC] - Catecholamine Synthesis Inhibitor

Mechanisms of Action [MoA] - Catecholamine Synthesis Inhibitors

Metyrosine is a Catecholamine Synthesis Inhibitor. The mechanism of action of metyrosine is as a Catecholamine Synthesis Inhibitor.

METYROSINE

MeSH Pharmacological ClassificationCompounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
Absorption, Distribution and Excretion · 2 件

Well absorbed from the gastrointestinal tract.

Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines, usually measured as decreased urinary excretion of catecholamines and their metabolites.

応用分野 · 3 件

使用A tyrosine hydroxylase inhibitor. An antihypertensive in pheochromocytoma

使用Metyrosine is the α-methyl derivative of tyrosine. It competitively inhibits tyrosine hydroxylase action, thus reducing the formation of epinephrine and norepinephrine. It is used for treating patients with pheochromocytoma, in cases where a rise in the level of catecholamines is observed.

一般的な説明Metyrosine (α-Methyl-L-tyrosine, Demser). Althoughinhibition of any of the three enzymes involved in CA biosynthesisshould decrease CAs, inhibitors of the first andthe rate-limiting enzyme TH would be the most effective.As such, metyrosine is a much more effective competitiveinhibitor of E and NE production than agents that inhibitany of the other enzymes involved in CA biosynthesis. Itis often possible to “fool” the enzymes into accepting astructurally similar and unnatural substrate such as metyrosine.Metyrosine differs structurally from tyrosine onlyin the presence of an α-methyl group . It is oneexample of a CA-biosynthesis inhibitor in clinical use.Although metyrosine is used as a racemic mixture, it is the (-)isomer that possesses the inhibitory activity.Metyrosine, which is given orally in dosages ranging from 1 to 4 g/day, is used principally for the preoperative managementof pheochromocytoma, chromaffin cell tumorsthat produce large amounts of NE and E. Although theseadrenal medullary tumors are often benign, patients frequentlysuffer hypertensive episodes. Metyrosine reducesthe frequency and severity of these episodes by significantlylowering CA production (35%–80%). The drug ispolar (log P=0.73) and excreted mainly unchanged in theurine. Because of its limited solubility in water caused byintramolecular bonding of the zwitterions, crystalluria is apotential serious side effect. It can be minimized by maintaininga daily urine volume of more than 2 L. Inhibitors ofCA synthesis have limited clinical utility because suchagents nonspecifically inhibit the formation of all CAs andresult in many side effects. Sedation is the most commonside effect of this drug.A similar example is the use of α-methyl-m-tyrosine inthe treatment of shock. It differs structurally from metyrosineonly in the presence of m-OH instead of p-OH inmetyrosine. This unnatural amino acid is accepted by the enzymesof the biosynthetic pathway and converted tometaraminol (an α-agonist).

補足説明 · 1 件

定義ChEBI: An L-tyrosine derivative that consists of L-tyrosine bering an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is us d to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma.